Finally, it was shown that CSF-1R targeting by the BLZ945 inhibitor could lead to the switch of the TAM phenotype toward an anti-tumor phenotype in a glioma preclinical model thanks to GM-CSF and IFN-γ produced by glioma cells concomitantly to TAM depletion [21]. The gene discussed is CSF2; the disease is central nervous system cancer.